Skip to main content
Premium Trial:

Request an Annual Quote

Corning, DNAPrint Genomics, Affymetrix, Eastman Kodak, President & Fellows of Harvard College, Agilent Technologies, Dr. Chip Biotechnology

Corning has received US Patent No. 7,105,347, “Method and device for protein delivery into cells.” The patent claims methods for performing surface-mediated protein delivery into living cells, and fabricating protein-transfected cell cluster arrays. According to the patent’s abstract, a protein-containing mixture is provided where the mixture is deposited onto a surface at defined locations as microspots. Cells are then plated onto the surface in sufficient density and under conditions for the proteins to be delivered into the cells. The protein-transfected cell arrays may then be used for direct screening of protein or enzymatic functions or any given intracellular protein interaction in the natural environment of a living cell. They can also be used for high-throughput screening of other biological and chemical analytes, which affect the functions of these proteins.

DNAPrint Genomics of Sarasota, Fla., has received US Patent No. 7,107,155, “Methods for the identification of genetic features for complex genetics classifiers.” A method is claimed where a candidate single nucleotide polymorphism combination is selected from a plurality of candidate SNP combinations for a gene associated with a genetic trait. Haplotype data associated with this candidate SNP combination is then read for a plurality of individuals and grouped into a positive-responding group and a negative-responding group based on whether a predetermined trait criteria for an individual is met. A statistical analysis on the grouped haplotype data is then performed to obtain a statistical measurement. The acts of selecting, reading, grouping, and performing are repeated as necessary to identity the candidate SNP combination having the optimal statistical measurement. The number of SNP combinations selected and analyzed may be reduced based on a simultaneous testing procedure, including the use of microarrays.

Affymetrix has received US Patent No. 7,108,472, “Cartridge loader and methods.” The patent claims a device for transporting cartridges that can hold a plurality of cartridges in a temperature-controlled environment. A transport system with a grasping mechanism for grasping the cartridges is also claimed. The transport system is further used to remove the cartridge from the housing and to place the cartridge into a scanner. According to the patent, the scanner is constructed and arranged to scan one or more probe arrays, where the probe arrays are disposed on a substrate that is coupled to the cartridge.

Eastman Kodak of Rochester, NY, has received US Patent No. 7,108,891, “Random array of microspheres.” The patent claims a method of making a microarray by: a) providing a support; b) coating a receiving layer on the support to receive microspheres; c) coating a dispersion of microspheres in a carrier fluid on the receiving layer; d) allowing the microspheres to partially submerge into the receiving layer; e) evaporating off the carrier fluid; and f) allowing crosslinking reaction between the receiving layer and the crosslinker in the carrier fluid.

Affymetrix and the President & Fellows of Harvard College of Cambridge, Mass., have received US Patent No. 7,108,969, “Methods for detecting and diagnosing oral cancer.” The patent claims methods of monitoring the expression of genes in malignant oral cells where gene expression profiles are used to identify markers associated with malignant oral cells and to diagnose oral cancer. According to the method, a population of nucleic acids is prepared from a sample of cells obtained from malignant oral tissue. The nucleic acids are then contacted to an array of probes and the relative hybridization of the probes to the nucleic acids is determined. Malignant oral cells can be classified by determining an expression profile of each of a plurality of cells derived from malignant oral tissue, and then classifying the cells in clusters determined by similarity of expression profile.

Agilent Technologies has received US Patent No. 7,108,979, “Methods to detect cross-contamination between samples contacted with a multi-array substrate.” The patent claims methods and compositions for detecting cross-contamination between samples contacted with different arrays of a multi-array substrate. The methods involve contacting sample to arrays of a multi-array substrate that contains cross-contamination probes in each of its arrays, and evaluating the resultant sample contacted arrays for cross-contamination between the samples. Kits and systems are claimed for performing the method and the patent states the methods may be used in various applications including gene expression analysis, DNA sequencing, and mutation detection.

Dr. Chip Biotechnology of Miao-Li, Taiwan, has received US Patent No. 7,109,024, “Biomolecule-bound substrates.” The patent claims a biomolecule-bound substrate that includes a support made of an organic polymer with an unmodified surface and a plurality of unmodified biomolecules immobilized on the unmodified surface. According to the patent, the biomolecules may include oligonucleotides. The substrate is formed by placing the unmodified biomolecules on the unmodified surface followed by ultraviolet irradiation.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.